Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience

Detalhes bibliográficos
Autor(a) principal: Martins, Carlos
Data de Publicação: 2005
Outros Autores: Lacerda, João, Lourenço, Fernanda, Carmo, José A., Lacerda, J. M. F.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/55251
Resumo: © Ordem dos Médicos
id RCAP_cb226cd7fa674460b80de72cd65dc83f
oai_identifier_str oai:repositorio.ul.pt:10451/55251
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experienceTransplante autólogo de células estaminais em leucemiamielóide aguda: factores com Influência na sobrevida: experiência de 13 anos de uma InstituiçãoAcute myeloid leukaemiaAutologous stem cell transplantation© Ordem dos MédicosWe report our results of autologous stem cell transplantation (SCT) in patients with AML during the last 13 years. Between August 1990 and December 2003, 42 patients with acute myeloid leukemia (AML) received an autologous SCT. Patients were classified as standard risk if first complete remission (CR) was induced after one or two chemotherapy regimens and the white blood cell count at presentation was below 50,000/mL (n=12), while patients requiring more than two induction regimens to attain first CR and with CR2 ou more advanced disease and/or had a higher white blood cell count at presentation were defined as high risk (n=30). Twenty one patients were transplanted in first CR. The median patient age was 24 years (range, 2-56 years), and the median time interval from diagnosis to autologous SCT was 9 months (range 3-87 months). The conditioning regimen for SCT consisted of busulfan (BU) 16 mg/kg and melfalan (MEL) 180 mg/m2 (BUMEL) in 17 (40%) patients and busulfan 16 mg/kg and VP-16 60 mg/kg (BUVP16) in 22 (52%) patients. Three patients received a different conditioning regimen with BCNU 300 mg/m2, VP16 2 g/m2 and melphalan 160 mg/m2 (BEM). Twenty five (60%) patients received bone marrow (BM), 11 (26%) patients received peripheral blood stem cells (PBSC) and 6 patients (14%) received BM plus PBSC. With a median follow-up of 7 years, the 13 year overall survival (OS) and diseasefree survival (DFS) of all patients is 52% and 40%, respectively. In univariate analysis, males had a significantly superior DFS than females (55% vs 22%, p=0.003), and patients younger than 15 years of age had significantly superior OS and DFS than older patients (50% vs 35%, p=0.05; and 50% vs 28%, p=0.03, respectively). Patients with FAB M3 subtype also had a superior OS than the other FAB subtypes (100% vs 44%, p=0.05). There was a strong statistical correlation between risk group and survival. In fact, the patients with standard risk had a superior OS and DFS than those with high risk disease (67% vs 23%, p=0.0004; and 50% vs 27%, p=0.01, respectively). When patients with FAB M3 disease were excluded from the analysis, the group with standard risk continue to have a superior OS and DFS (67% vs 13%, p=0.008; and 50% vs 14%, p=0.02, respectively). We conclude that autologous SCT is an effective treatment in AML with the possibility of long survivorship, particularly in patients with standard risk disease.Ordem dos MédicosRepositório da Universidade de LisboaMartins, CarlosLacerda, JoãoLourenço, FernandaCarmo, José A.Lacerda, J. M. F.2022-11-25T16:13:56Z20052005-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/55251engActa Med Port. 2005 Sep-Oct;18(5):329-3370870-399X1646-0758info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:02:06Zoai:repositorio.ul.pt:10451/55251Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:05:56.693986Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
Transplante autólogo de células estaminais em leucemiamielóide aguda: factores com Influência na sobrevida: experiência de 13 anos de uma Instituição
title Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
spellingShingle Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
Martins, Carlos
Acute myeloid leukaemia
Autologous stem cell transplantation
title_short Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
title_full Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
title_fullStr Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
title_full_unstemmed Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
title_sort Autologous stem cell transplantation in acute myeloid leukemia: factors influencing outcome: a 13 year single institution experience
author Martins, Carlos
author_facet Martins, Carlos
Lacerda, João
Lourenço, Fernanda
Carmo, José A.
Lacerda, J. M. F.
author_role author
author2 Lacerda, João
Lourenço, Fernanda
Carmo, José A.
Lacerda, J. M. F.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Martins, Carlos
Lacerda, João
Lourenço, Fernanda
Carmo, José A.
Lacerda, J. M. F.
dc.subject.por.fl_str_mv Acute myeloid leukaemia
Autologous stem cell transplantation
topic Acute myeloid leukaemia
Autologous stem cell transplantation
description © Ordem dos Médicos
publishDate 2005
dc.date.none.fl_str_mv 2005
2005-01-01T00:00:00Z
2022-11-25T16:13:56Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/55251
url http://hdl.handle.net/10451/55251
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Acta Med Port. 2005 Sep-Oct;18(5):329-337
0870-399X
1646-0758
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134612073480192

Registros relacionados